Chewable Tablet Adverse Events, Manufacturing Slips Prompt Guidance
This article was originally published in The Tan Sheet
Chewable tablet manufacturers are overlooking quality attributes, leading to adverse events, according to an FDA draft guidance. The agency recommends firms establish hardness, dissolution and disintegration of products early in manufacturing.
You may also be interested in...
Avadim Health could get FTC scrutiny after it declines to comply with two findings by an industry self-regulation group to discontinue 26 claims for its Theraworx Relief homeopathic products. It says the analysis “misapplied the well-recognized standards of substantiation” established by FTC.
HOWARU Calm contains probiotic strain Lpc-37 (L. paracasei) and can be added to supplements or formulated into new products, says DuPont Nutrition & Biosciences. It reports that 65% of adults worldwide are experiencing some daily stress.
Amazon requires firms selling supplements on its site in the US to demonstrate their products comply with FDA regulations for labeling and GMPs. Marketers that don’t submit documentation face removal of their products from the site.